PROTACs
-
PROTACs Related Products (458)
Related Products (458)
-
PROTAC BRD4 Degrader-35
0 ImagesCat. No.: HY-177041CAS No.: 2503035-53-6PROTAC BRD4 Degrader-35 (Compound 17) is a PROTAC degrader of BRD4. PROTAC BRD4 Degrader-35 can be studied in anticancer research.
-
PROTAC SMARCA2 degrader-6
0 ImagesCat. No.: HY-159450CAS No.: 2568523-72-6
-
PROTAC 20S proteasome subunit β5 degrader 2
0 ImagesCat. No.: HY-169135PROTAC 20S proteasome subunit β5 degrader 2 is a PROTAC degrader targeting the 20S proteasome subunit β5, with a DC50 of 0.16 μM. PROTAC 20S proteasome subunit β5 degrader 2 forms a ternary complex with the CRBN E3 ligase, induces ubiquitination of the 20S proteasome subunit β5, and promotes its degradation via the proteasome. PROTAC 20S proteasome subunit β5 degrader 2 exerts antiproliferative effects in cancer cells and exhibits antitumor activity both in vitro and in vivo. It can be used for the research of pharyngeal cancer and drug-resistant multiple myeloma.
-
PROTAC 11β-HSD1 Degrader 1
0 ImagesCat. No.: HY-179602PROTAC 11β-HSD1 Degrader 1 is a highly efficient PROTAC targeting 11β-HSD1 (Hydroxysteroid 11-beta dehydrogenase 1). PROTAC 11β-HSD1 Degrader 1 demonstrates ubiquitin-proteasome-dependent degradation of 11β-HSD1. PROTAC 11β-HSD1 Degrader 1 can be used for the study of type 2 diabetes mellitus (T2DM).
-
PROTAC sEH degrader-5
0 ImagesCat. No.: HY-187425CAS No.: 3123230-60-1PROTAC sEH degrader-5 is a highly efficient PROTAC degrader that targets and degrades soluble epoxide hydrolase (sEH) by recruiting cereblon. PROTAC sEH degrader-5 directly inhibits the hydrolase activity of human and mouse sEH, with pIC50 values of 10.36 and 8.41, respectively. PROTAC sEH degrader-5 alleviates LPS (HY-D1056)-induced acute inflammation in vivo. PROTAC sEH degrader-5 can be used in studies related to LPS-induced acute inflammation.
-
PROTAC BTK Degrader-4
0 ImagesCat. No.: HY-128408CAS No.: 2893795-12-3PROTAC BTK Degrader-4 (compound 15) is a potent PROTAC Bruton's tyrosine kinases (BTK) degrader (DC50 < 100 nM) with little immunomodulatory imide drug (IMiD) activity (DC50 = 0.345 μM, Dmax = 27.4%). PROTAC BTK Degrader-4 can be used for cancers, autoimmune diseases, and inflammatory diseases that are mediated by BTK.
-
PROTAC BRM/BRG1 degrader-3
0 ImagesCat. No.: HY-168251CAS No.: 2933125-05-2PROTAC BRM/BRG1 degrader-3 is a BRM/BRG1 PROTAC degrader, exhibiting a DC50 of less than 1 nM for BRM degradation and a DC50 of greater than 1 nM for BRG1 degradation in SW1573 cells. PROTAC BRM/BRG1 degrader-3 shows moderate inhibitory activity against CYP2D6 and hERG. PROTAC BRM/BRG1 degrader-3 inhibits cancer cell proliferation and tumor tissue growth, and exhibits favorable metabolic stability in liver microsomes. PROTAC BRM/BRG1 degrader-3 can be used in non-small cell lung cancer-related research.
-
PROTAC BRM/BRG1 degrader-2
0 ImagesCat. No.: HY-168247CAS No.: 2933124-32-2
-
PROTAC GDI2 Degrader-1
0 ImagesCat. No.: HY-156244PROTAC GDI2 Degrader-1 is a GDI2 PROTAC degrader with a DC50 value of 1.48 μM and a Kd value of 23.9 μM. PROTAC GDI2 Degrader-1 triggers paraptosis in tumor cells via endoplasmic reticulum expansion and fusion, endoplasmic reticulum stress, unfolded protein response, and cytoplasmic vacuolization. PROTAC GDI2 Degrader-1 exhibits significant in vivo anti-tumor activity in pancreatic cancer xenograft models. PROTAC GDI2 Degrader-1 can be used for research related to pancreatic cancer.
-
SN38-(PEG)2-Pom-α
0 ImagesCat. No.: HY-180555SN38-(PEG)2-Pom-α is a selective PROTAC RPL15 degrader. SN38-(PEG)2-Pom-α induces ubiquitin-mediated degradation of RPL15 without affecting TOP1. SN38-(PEG)2-Pom-α induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. SN38-(PEG)2-Pom-α enhances anti-PD-1 immunotherapy in a murine melanoma tumor model expressing human CRBN. SN38-(PEG)2-Pom-α can be used for melanoma research.
-
MS5033
0 ImagesCat. No.: HY-143882CAS No.: 2376137-29-8MS5033 is a potent PROTAC-based AKT (protein kinase B) degrader, with a DC50 of 430 nM in PC3 cells.
-
PROTAC EZH2 Degrader-19
0 ImagesCat. No.: HY-181320CAS No.: 2653338-65-7PROTAC EZH2 Degrader-19 (compound 6) is a is a PROTAC protein degrader targeting EZH2 with an IC50 of 15.00 nM. PROTAC EZH2 Degrader-19 induces strong degradation of all PRC2 subunits (EZH2, SUZ12, EED, RbAp48) in a concentration- and time-dependent manner.PROTAC EZH2 Degrader-19 exhibits antiproliferative effects in cancer cells.PROTAC EZH2 Degrader-19 can be used for the research of cancer.
-
cis-VZ185
0 ImagesCat. No.: HY-114322ACAS No.: 2306193-98-4cis-VZ185 serves as a non-degradative control and inactive analog of VZ185 (HY-114322), a dual-target BRD7/BRD9 degrader PROTAC. cis-VZ185 exerts antiproliferative activity against epithelioid sarcoma cells only at high concentrations. cis-VZ185 induces morphological changes in osteosarcoma cells. cis-VZ185 can be used in studies related to epithelioid sarcoma.
-
MPD2
0 ImagesCat. No.: HY-162464MPD2 is a Cereblon (CRBN) ligand and SARS-CoV-2 MPro degrader with an IC50 <1000 nM against SARS-CoV-2 MPro[1]. MPD2 engages CRBN to mediate ubiquitination and proteasomal degradation of SARS-CoV-2 MPro, reducing SARS-CoV-2 MPro protein levels in infected cells. MPD2 inhibits viral replication of various SARS-CoV-2 strains and acts against nirmatrelvir-resistant SARS-CoV-2 viruses. MPD2 can be used for the research of covid-19 and for fighting against drug-resistant viral variants..
-
XF056-132
0 ImagesCat. No.: HY-150400ACAS No.: 2694057-55-9Synonyms: MS132N TFAXF056-132 (MS132N TFA) is an inactive WDR5 PROTAC degrader with a Kd value of 106 nM against human targets, and exhibits no significant binding to the VHL complex, serves as a negative control for MS132. XF056-132 binds to WDR5, does not induce WDR5 degradation in pancreatic cancer cells, and exerts no inhibitory effect on adenocarcinoma cells. XF056-132 can be used in the research of pancreatic ductal adenocarcinoma.
-
PROTAC WDR5 degrader 1
0 ImagesCat. No.: HY-168487CAS No.: 2737222-94-3PROTAC WDR5 degrader 1 is a heterobifunctional WDR5 PROTAC degrader with a DC50 value of 53 nM and a Kd value of 18 nM, exhibiting selective WDR5 degradation activity and cell permeability. PROTAC WDR5 degrader 1 induces proliferation defects in leukemia cells, with enhanced efficacy in cells overexpressing VHL. PROTAC WDR5 degrader 1 is applicable to research related to acute myeloid leukemia.
-
PROTAC TSSK1 Degrader-2
0 ImagesCat. No.: HY-184464PROTAC TSSK1 Degrader-2 is a cereblon-recruiting PROTAC degrader targeting TSSK1, with a DC50 of 10.8 nM and an IC50 of 56.8 nM against TSSK1. PROTAC TSSK1 Degrader-2 recruits the cereblon E3 ubiquitin ligase to induce proteasomal degradation of TSSK1. PROTAC TSSK1 Degrader-2 reduces the motility and in vitro fertilization capacity of mouse sperm. PROTAC TSSK1 Degrader-2 undergoes metabolic N-dealkylation and exhibits high efflux. PROTAC TSSK1 Degrader-2 can be used in studies related to male fertility.
-
PROTAC erf3a Degrader-2
0 ImagesCat. No.: HY-163938ACAS No.: 3033871-15-4PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer.
